Arkolith/Insider Trading/RXRX/Form 4

Bumpus Namandje

DirectorRECURSION PHARMACEUTICALS, INC. (RXRX) · full profile →Form 4 · filed Jun 22, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$13K
Net Open-Market Flow
-$13K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 18, 2026Sell(S)4K$3.18$13K128K
Jun 17, 2026Grant(A)88K—$0132K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001601830-26-000082) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML